AST SpaceMobile, Inc.
ASTS has a real path to a strategic satellite-to-cellular network, but at 151.79x sales and with repeated EPS misses, the stock already prices in much of the 2027 commercialization story before execution is proven.
ASTS is no longer a binary financing story. It is a timing and proof story. The company now has pro forma cash of over $3.7B, a $1.3B backlog, and a clearer construction roadmap, with BlueBird 14-16 ready to ship, 17-46 in production or assembly, and management targeting roughly 45 satellites in orbit by early 2027. Those are real assets. They make the long-term concept credible enough that a zero is off the table absent major technical failure.
The issue at $61.56 is that the market is still paying heavily in advance for 2027 and later economics that have not yet shown up in the numbers. FY2025 revenue was just $0.1B, operating margin was -5397.5%, and FY2025 EPS was -1.34. In Q2 2026, revenue was $31.5M, but EBITDA was still -$0.25B, and management reiterated rather than raised FY26 revenue guidance of $150M-$200M despite the strong sequential step-up. That matters because the stock trades at 151.79x sales against a peer average of 4.1x. Even for a unique asset, that is a valuation that requires close to flawless execution on launches, service activation, regulatory approvals, and customer monetization.
The case depends on three things. First, the Q4-weighted 2026 plan has to convert into actual reported revenue, not another push-out caused by milestone timing. Management explicitly said, "We expect revenue in each quarter to continue to grow sequentially but will likely be weighted towards the fourth quarter." Second, the company has to turn constellation spending into network coverage on the stated timeline. CapEx was $610M in Q2 alone, and FY26 adjusted OpEx is about $400M, so the burn rate is still substantial. Third, the government opportunity has to move from narrative to contracts and then to recurring revenue. Management said, "What we're seeing is that this opportunity is going to start scaling up into a recurring multibillion dollar a year opportunity starting in 2027." That may be true, but the market is already paying as if a meaningful slice of that is likely.
The stock is down 54.0% from its high and 24.7% below its 200-day average, so sentiment has cooled. That reduces some speculative excess, but not enough to create a clear margin of safety given the valuation. A HOLD is the right call until ASTS either proves the 2027 revenue engine or the stock offers a much cheaper entry point.
Launches and service milestones land on time, government awards accelerate toward management's 2027 ambition, and investors reprice ASTS as a scarce global direct-to-cell platform.
ASTS meets the $150M-$200M FY26 framework, preserves the early-2027 coverage path, and valuation stays rich but supported by backlog and liquidity.
Q4-weighted revenue slips, early-2027 coverage timing moves right, and the market compresses a triple-digit sales multiple as losses remain near current run rate.
Quant call (HOLD) diverges from analyst consensus (Strong Buy: 3 buy / 3 hold / 0 sell) — resolve explicitly.
We don't buy stocks where they are, we buy them where they're going.
Forward earnings power is still a 2027 and later debate, not a 2026 reality. Trailing P/E is not meaningful because EPS is -1.34, and even forward valuation is being carried by a future recurring-revenue story that depends on turning $1.3B backlog and government demand into operating leverage after a year with roughly $400M of adjusted OpEx and heavy launch CapEx. The moat looks better in three to five years if ASTS reaches continuous coverage first with direct-to-device capability and partner distribution, but right now that moat is still being built rather than harvested. AI helps more than it hurts, mainly through network optimization, satellite operations, and defense demand, but it does not change the core gating items, which are launches, regulatory permissions, and monetization speed.
- FY26 revenue guidance of $150M-$200M versus FY2025 revenue of $0.1B, with management still expecting growth to be Q4-weighted.
- $1.3B backlog and management's view that government can become a multibillion-dollar annual opportunity starting in 2027.
- Valuation remains extreme at 151.79x P/S versus 4.1x peer average, even after the stock fell 54.0% from its $133.86 high.
- Liquidity is no longer the near-term problem. ASTS added $1.15B of convertible notes and ended the quarter with cash of over $3.7B pro forma, while the current ratio is 13.05.
- Commercialization is advancing. Q2 revenue reached $31.5M, more than double Q1, and management said BlueBird 14-16 are ready to ship with 17-46 in production or assembly.
- The network build is becoming more concrete. Management is targeting approximately 45 satellites in orbit by early 2027, enough to support continuous service in key markets.
- Strategic demand is forming before full network availability. Backlog increased to $1.3B, helped by new government awards and contracted commercial programs.
- Current fundamentals remain deeply negative. FY2025 operating margin was -5397.5%, net margin -7033.2%, and Q2 2026 EBITDA margin was -799.7% on only $0.03B of revenue.
- Execution against Street expectations has been weak. ASTS missed EPS in 7 of the last 8 reported quarters, including misses of -158.8% in May 2026 and -144.4% in August 2026.
- Costs are climbing as the company scales. FY26 adjusted OpEx excluding cost of revenues is about $400M, Q3 OpEx is guided to $105M-$115M, and Q2 CapEx was $610M.
- The stock still discounts a lot of future success. ASTS trades at 151.79x sales versus a peer average of 4.1x, with peer dispersion of 7.2x, limiting support from comps.
| Metric | Value | Context |
|---|---|---|
| Quant price target | $67.02 | Engine base case, 8.9% above current $61.56, Medium confidence |
| Market cap | $23.8B | Large value assigned ahead of full commercial scale |
| FY2025 revenue | $0.1B | 231.1% YoY, still very small versus valuation |
| FY2025 EPS | -$1.34 | Still loss-making, though 58.7% YoY improvement |
| FY2025 operating margin | -5397.5% | Improved from -5494.8%, but economics remain pre-scale |
| Valuation | 151.79x P/S | Versus peer average 4.1x |
| Balance sheet | Debt/Equity 1.58, Current ratio 13.05, Total debt $3.0B | Liquidity strong, leverage meaningful after capital raising |
| Free cash flow | -$0.7B | Heavy investment phase, no self-funding yet |
| FY2026 guidance | $150M-$200M revenue, ~$400M adjusted OpEx, $350M-$425M Q3 CapEx | Revenue still expected to be Q4-weighted |
| Backlog | $1.3B | Increased on government awards and contracted commercial programs |
| Earnings track record | 7 misses in last 8 quarters | Latest miss -144.4% on 2026-08-10 |
| Price action | -54.0% vs 52-week high, -24.7% vs 200-day average | Sentiment reset is significant, but trend remains weak |
The biggest risk is that the heavily Q4-weighted FY26 revenue target of $150M-$200M slips on launch, deployment, or milestone timing, which would hit a stock still valued at 151.79x sales.
The next catalyst is the November 9, 2026 earnings report, specifically whether sequential revenue growth stays on track for the reiterated $150M-$200M FY26 target and whether satellite deployment timing still supports roughly 45 satellites by early 2027.
Positioning is volatile. The top three institutions hold 36.5%, insiders own 14.1%, and short interest is elevated at 24.12% of shares, or 64.1M shares with 3.5 days to cover, which keeps squeeze potential alive around catalysts. Options positioning is mildly supportive near spot because the zero-gamma level is $60.18, only 1.57% from the current price, and the regime is positive, but that does not offset the larger reality that the stock is still 24.7% below its 200-day average and 54.0% below its high.
Current revenue is still early-stage and milestone-driven rather than broad recurring service revenue.
A meaningful driver of the recent backlog increase to $1.3B, with management calling out a potential multibillion-dollar annual opportunity from 2027.
Q2 2026 revenue of $31.5M was driven by gateway deliveries and U.S. government milestones, underscoring how lumpy the present model remains.
ASTS reiterated FY26 revenue and outlined a Q4-weighted ramp toward early-2027 coverage milestones.
Execution has been mixed. On the positive side, management's late-2024 claim that launch capacity had been secured for 45-60 satellites and that the first five BlueBirds were operating as expected now lines up with a more advanced manufacturing posture, with BlueBird 14-16 ready to ship, 17-46 in production or assembly, and an early-2027 target of about 45 satellites in orbit. The cost framework has drifted higher but not catastrophically, moving from $19M-$21M per satellite in the 2024 Q3 call to $21M-$23M now. The weaker read is financial execution: Q4 2024 adjusted OpEx ex-ASIC was guided to $30M-$35M, while FY26 adjusted OpEx ex-cost of revenues is now about $400M, or roughly $100M per quarter, and the company has missed EPS expectations in 7 of the last 8 quarters. Management has broadly advanced the strategic plan, but the repeated earnings misses and rising cost base argue for only moderate credibility until revenue conversion catches up.
We remain confident in our ability to achieve our full year 2026 revenue goals and are reiterating our guidance of $150 million to $200 million, supported by contracted programs already underway together with our existing commercial and government pipeline.
For the third quarter of 2026, we estimate that our adjusted operating expenses, excluding adjusted cost of revenues will increase to the range of approximately $105 million to $115 million.
We expect revenue in each quarter to continue to grow sequentially but will likely be weighted towards the fourth quarter.
We achieved over $30 million in revenue during the quarter, more than doubling our Q1 revenue.
What we're seeing is that this opportunity is going to start scaling up into a recurring multibillion dollar a year opportunity starting in 2027.
ASTS's moat is the combination of direct-to-standard-cellphone satellite architecture, scarce spectrum and regulatory positioning, and partnerships with major telecom and strategic investors. If the company reaches roughly 45 satellites by early 2027 and demonstrates reliable service economics, that moat becomes much more durable because late entrants would face years of launch, capital, and integration catch-up. Today, however, the moat is still partly aspirational because it has not yet translated into recurring high-margin service revenue.
Capital allocation is focused almost entirely on constellation build-out. There are no buybacks and no dividends, while FCF was -$0.7B and Q2 CapEx alone was $610M, driven by launch payments, satellite materials, labor, and facility equipment. That is rational for this phase, and the $1.15B convert raise plus pro forma cash above $3.7B buys time, but discipline now depends on converting this spend into on-schedule coverage and contracted revenue rather than simply extending the investment cycle.
ASTS rates a HOLD with Medium conviction. The company has moved beyond proof-of-concept and now has enough capital and backlog to make the 2027 network story real, but the stock still prices in a lot of that success before revenue and margins validate it. At 151.79x sales, this is not an execution-for-free setup. A more positive view would require evidence that the $150M-$200M FY26 target is landing cleanly and that the early-2027 satellite coverage milestone remains on schedule. A more negative view would follow another material revenue timing slip or a further step-up in spending without matching backlog conversion.
≣ Full research note tap to expand
Executive Summary
HOLD, Medium conviction. ASTS rates a HOLD at Medium conviction. The company has tangible operating progress, including $1.3B backlog, pro forma cash above $3.7B, and a target of roughly 45 BlueBird satellites by early 2027, but the current $23.8B market cap still sits far ahead of present revenue and earnings power. The setup is no longer one of balance-sheet survival, it is one of whether management can convert a Q4-weighted 2026 ramp into credible 2027 recurring revenue without another round of timeline or cost slippage.
Investment Thesis
ASTS is no longer a binary financing story. It is a timing and proof story. The company now has pro forma cash of over $3.7B, a $1.3B backlog, and a clearer construction roadmap, with BlueBird 14-16 ready to ship, 17-46 in production or assembly, and management targeting roughly 45 satellites in orbit by early 2027. Those are real assets. They make the long-term concept credible enough that a zero is off the table absent major technical failure.
The issue at $61.56 is that the market is still paying heavily in advance for 2027 and later economics that have not yet shown up in the numbers. FY2025 revenue was just $0.1B, operating margin was -5397.5%, and FY2025 EPS was -1.34. In Q2 2026, revenue was $31.5M, but EBITDA was still -$0.25B, and management reiterated rather than raised FY26 revenue guidance of $150M-$200M despite the strong sequential step-up. That matters because the stock trades at 151.79x sales against a peer average of 4.1x. Even for a unique asset, that is a valuation that requires close to flawless execution on launches, service activation, regulatory approvals, and customer monetization.
The case depends on three things. First, the Q4-weighted 2026 plan has to convert into actual reported revenue, not another push-out caused by milestone timing. Management explicitly said, "We expect revenue in each quarter to continue to grow sequentially but will likely be weighted towards the fourth quarter." Second, the company has to turn constellation spending into network coverage on the stated timeline. CapEx was $610M in Q2 alone, and FY26 adjusted OpEx is about $400M, so the burn rate is still substantial. Third, the government opportunity has to move from narrative to contracts and then to recurring revenue. Management said, "What we're seeing is that this opportunity is going to start scaling up into a recurring multibillion dollar a year opportunity starting in 2027." That may be true, but the market is already paying as if a meaningful slice of that is likely.
The stock is down 54.0% from its high and 24.7% below its 200-day average, so sentiment has cooled. That reduces some speculative excess, but not enough to create a clear margin of safety given the valuation. A HOLD is the right call until ASTS either proves the 2027 revenue engine or the stock offers a much cheaper entry point.
Key Metrics
| Metric | Value | Context |
|---|---|---|
| Quant price target | $67.02 | Engine base case, 8.9% above current $61.56, Medium confidence |
| Market cap | $23.8B | Large value assigned ahead of full commercial scale |
| FY2025 revenue | $0.1B | 231.1% YoY, still very small versus valuation |
| FY2025 EPS | -$1.34 | Still loss-making, though 58.7% YoY improvement |
| FY2025 operating margin | -5397.5% | Improved from -5494.8%, but economics remain pre-scale |
| Valuation | 151.79x P/S | Versus peer average 4.1x |
| Balance sheet | Debt/Equity 1.58, Current ratio 13.05, Total debt $3.0B | Liquidity strong, leverage meaningful after capital raising |
| Free cash flow | -$0.7B | Heavy investment phase, no self-funding yet |
| FY2026 guidance | $150M-$200M revenue, ~$400M adjusted OpEx, $350M-$425M Q3 CapEx | Revenue still expected to be Q4-weighted |
| Backlog | $1.3B | Increased on government awards and contracted commercial programs |
| Earnings track record | 7 misses in last 8 quarters | Latest miss -144.4% on 2026-08-10 |
| Price action | -54.0% vs 52-week high, -24.7% vs 200-day average | Sentiment reset is significant, but trend remains weak |
Financial Strength
The balance sheet is strong enough to fund the next stage of deployment, which is the most important positive change in the story. Pro forma cash of over $3.7B and a 13.05 current ratio reduce near-term financing risk materially, even with $3.0B of debt and negative FCF of $0.7B. The problem is not liquidity, it is economic conversion. Margins remain deeply negative, and spending is still climbing as launch and production scale, so investors are underwriting years of future operating leverage rather than any present cash generation.
Competitive Position
ASTS's moat is the combination of direct-to-standard-cellphone satellite architecture, scarce spectrum and regulatory positioning, and partnerships with major telecom and strategic investors. If the company reaches roughly 45 satellites by early 2027 and demonstrates reliable service economics, that moat becomes much more durable because late entrants would face years of launch, capital, and integration catch-up. Today, however, the moat is still partly aspirational because it has not yet translated into recurring high-margin service revenue.
Management & Guidance
Management reiterated FY26 revenue guidance of $150M-$200M and was explicit that the year remains Q4-weighted. Scott Wisniewski said, "We remain confident in our ability to achieve our full year 2026 revenue goals and are reiterating our guidance of $150 million to $200 million, supported by contracted programs already underway together with our existing commercial and government pipeline," while Andrew Johnson added, "We expect revenue in each quarter to continue to grow sequentially but will likely be weighted towards the fourth quarter." That guidance is plausible given the backlog and milestone cadence, but credibility is only moderate because ASTS has repeatedly missed EPS expectations and because OpEx and CapEx continue to trend high, with Q3 adjusted OpEx guided to $105M-$115M and Q2 CapEx already at $610M.
Segment Analysis
- Commercial and partner service revenue (Not separately disclosed): Current revenue is still early-stage and milestone-driven rather than broad recurring service revenue.
- Government contracts (Not separately disclosed): A meaningful driver of the recent backlog increase to $1.3B, with management calling out a potential multibillion-dollar annual opportunity from 2027.
- Gateway deliveries and milestone revenue (Material within current revenue base): Q2 2026 revenue of $31.5M was driven by gateway deliveries and U.S. government milestones, underscoring how lumpy the present model remains.
Capital Allocation
Capital allocation is focused almost entirely on constellation build-out. There are no buybacks and no dividends, while FCF was -$0.7B and Q2 CapEx alone was $610M, driven by launch payments, satellite materials, labor, and facility equipment. That is rational for this phase, and the $1.15B convert raise plus pro forma cash above $3.7B buys time, but discipline now depends on converting this spend into on-schedule coverage and contracted revenue rather than simply extending the investment cycle.
Management Execution & Track Record
Execution has been mixed. On the positive side, management's late-2024 claim that launch capacity had been secured for 45-60 satellites and that the first five BlueBirds were operating as expected now lines up with a more advanced manufacturing posture, with BlueBird 14-16 ready to ship, 17-46 in production or assembly, and an early-2027 target of about 45 satellites in orbit. The cost framework has drifted higher but not catastrophically, moving from $19M-$21M per satellite in the 2024 Q3 call to $21M-$23M now. The weaker read is financial execution: Q4 2024 adjusted OpEx ex-ASIC was guided to $30M-$35M, while FY26 adjusted OpEx ex-cost of revenues is now about $400M, or roughly $100M per quarter, and the company has missed EPS expectations in 7 of the last 8 quarters. Management has broadly advanced the strategic plan, but the repeated earnings misses and rising cost base argue for only moderate credibility until revenue conversion catches up.
Positioning & Flows
Positioning is volatile. The top three institutions hold 36.5%, insiders own 14.1%, and short interest is elevated at 24.12% of shares, or 64.1M shares with 3.5 days to cover, which keeps squeeze potential alive around catalysts. Options positioning is mildly supportive near spot because the zero-gamma level is $60.18, only 1.57% from the current price, and the regime is positive, but that does not offset the larger reality that the stock is still 24.7% below its 200-day average and 54.0% below its high.
Bull Case
- Liquidity is no longer the near-term problem. ASTS added $1.15B of convertible notes and ended the quarter with cash of over $3.7B pro forma, while the current ratio is 13.05.
- Commercialization is advancing. Q2 revenue reached $31.5M, more than double Q1, and management said BlueBird 14-16 are ready to ship with 17-46 in production or assembly.
- The network build is becoming more concrete. Management is targeting approximately 45 satellites in orbit by early 2027, enough to support continuous service in key markets.
- Strategic demand is forming before full network availability. Backlog increased to $1.3B, helped by new government awards and contracted commercial programs.
Bear Case
- Current fundamentals remain deeply negative. FY2025 operating margin was -5397.5%, net margin -7033.2%, and Q2 2026 EBITDA margin was -799.7% on only $0.03B of revenue.
- Execution against Street expectations has been weak. ASTS missed EPS in 7 of the last 8 reported quarters, including misses of -158.8% in May 2026 and -144.4% in August 2026.
- Costs are climbing as the company scales. FY26 adjusted OpEx excluding cost of revenues is about $400M, Q3 OpEx is guided to $105M-$115M, and Q2 CapEx was $610M.
- The stock still discounts a lot of future success. ASTS trades at 151.79x sales versus a peer average of 4.1x, with peer dispersion of 7.2x, limiting support from comps.
Valuation & Price Target
Engine price target $67.02 (+8.9% vs current), Medium confidence.
- P/S Multiple: $0.94 (2% weight)
- Quality-adjusted: $73.87 (20% weight)
The rating stays aligned with the quant baseline of HOLD. The engine's $67.02 price target implies only 8.9% upside from $61.56, which is not enough compensation for a company trading at 151.79x sales, generating -$0.7B of FCF, and missing EPS in 7 of the last 8 quarters. The more optimistic sell-side consensus is low-signal context here, especially because comparables are weak, with a peer average P/E of 38.6 and wide dispersion of 7.2x, while ASTS has no meaningful earnings base yet. The stock is materially off its highs, but that alone is not a reason to override valuation and execution risk.
Risk Assessment
Risk score 34/100 (Low). The biggest risk is that the heavily Q4-weighted FY26 revenue target of $150M-$200M slips on launch, deployment, or milestone timing, which would hit a stock still valued at 151.79x sales.
The Bottom Line
ASTS rates a HOLD with Medium conviction. The company has moved beyond proof-of-concept and now has enough capital and backlog to make the 2027 network story real, but the stock still prices in a lot of that success before revenue and margins validate it. At 151.79x sales, this is not an execution-for-free setup. A more positive view would require evidence that the $150M-$200M FY26 target is landing cleanly and that the early-2027 satellite coverage milestone remains on schedule. A more negative view would follow another material revenue timing slip or a further step-up in spending without matching backlog conversion.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr